Amer Zeidan: Why CROs shouldn’t be doing clinical research
Amer Zeidan shared on X:
“If you have any doubt why CROs shouldn’t be doing clinical research; just read from a CRO monitor: ‘Subject x was expected to get aza for 7 days consecutively but D7 was given on D8 bc D7 was thanksgiving day. Please verify you understand dosing and whether immediate reporting is needed.’
My response to this ‘which I didn’t actually write’ was to ‘Please verify you have a heart to ask us to deprive a cancer patient from their potentially last thanksgiving with their family for a clinically meaningless reason and just to find things to fill in your report’…”
Source: Amer Zeidan/X
Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center.
Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.